Adlai Nortye (NASDAQ:ANL) Shares Gap Up to $12.40

Adlai Nortye Ltd. (NASDAQ:ANL)’s share price gapped up before the market opened on Monday . The stock had previously closed at $12.40, but opened at $13.75. Adlai Nortye shares last traded at $13.75, with a volume of 27,872 shares.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a report on Friday, January 12th.

Adlai Nortye Trading Down 13.6 %

The company’s fifty day simple moving average is $9.08 and its two-hundred day simple moving average is $9.25.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.